Document:

exv10w10

Exhibit 10.10

The 2006 Omnibus Stock and Performance

Incentive Plan of GeoEye, Inc.

2009 Annual Performance Award Policy

     The purpose of this 2009 Performance Award Policy (the “Policy”) is to set forth the
performance criteria with respect to the payment of annual cash performance awards (“Performance
Awards”) to executives of GeoEye, Inc. (the “Company”) for the Company’s 2009 fiscal year pursuant
to the 2006 Omnibus Stock and Performance Incentive Plan of GeoEye, Inc. (the “Plan”).

Target Performance Awards

     Each executive set forth on Exhibit A (the “Participants”) who remains employed by the
Company through December 31, 2009, will be eligible for a Performance Award pursuant to the Plan
for the 2009 fiscal year in an amount based on (i) the target percentage of such participant’s base
salary set forth below and (ii) the funding of the Performance Award Pool (as defined below) based
on the percentage of the revenue and EBITDA targets achieved for the 2009 fiscal year.

Revenue and EBITDA Targets

     For the 2009 fiscal year, the revenue target is $[***] million and the EBITDA target is $[***]
million. These targets are derived from the budget submitted to the Board in December 2008.

Performance Award Pool

     Annual Performance Awards will be paid to Participants out of a funded pool (the “Performance
Award Pool”) equal to the sum of the target Performance Awards for all Participants. The
Performance Award Pool will be adjusted up or down based on actual Company financial performance.

     The range of Performance Award Pool funding is based on achievement of between 75% and 125% of
the revenue and EBITDA targets. Failure to achieve at least 75% of each of the revenue and EBITDA
targets will result in no funding of the Performance Award Pool.

     25% of the Performance Award Pool will fund upon achievement of 75% of the revenue and EBITDA
targets. An additional 1% of the Performance Award Pool will be funded for every 1% of revenue and
EBITDA target achievement between 75% and 100%, and an additional 2% for every 1% of revenue and
EBITDA target achievement between 100% and 125%. Funding will be capped at 200% of individual
Performance Award targets upon achieving 125% of both the revenue and EBITDA targets. The
following chart sets forth the funding of the Performance Award Pool:

 

			
	[***]	 	Means that certain confidential information has been deleted from this document and filed
separately with the Securities and Exchange Commission.

 

 

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	Revenues	 	EBITDA	 	Total Bonus Pool Funded
	% Achievement	 	% of Bonus	 	Bonus Pool	 	% of Bonus	 	Bonus Pool	 	 	 	 
	of Goal	 	Pool Funded	 	Funded $	 	Pool Funded	 	Funded $	 	%	 	$
	 	<75	%	 	 	0	%	 	$	[***]	 	 	 	0	%	 	$	[***]	 	 	 	0	%	 	$	[***]	 
	 	75	%	 	 	25	%	 	$	[***]	 	 	 	25	%	 	$	[***]	 	 	 	50	%	 	$	[***]	 
	 	80	%	 	 	30	%	 	$	[***]	 	 	 	30	%	 	$	[***]	 	 	 	60	%	 	$	[***]	 
	 	85	%	 	 	35	%	 	$	[***]	 	 	 	35	%	 	$	[***]	 	 	 	70	%	 	$	[***]	 
	 	90	%	 	 	40	%	 	$	[***]	 	 	 	40	%	 	$	[***]	 	 	 	80	%	 	$	[***]	 
	 	95	%	 	 	45	%	 	$	[***]	 	 	 	45	%	 	$	[***]	 	 	 	90	%	 	$	[***]	 
	 	100	%	 	 	50	%	 	$	[***]	 	 	 	50	%	 	$	[***]	 	 	 	100	%	 	$	[***]	 
	 	105	%	 	 	60	%	 	$	[***]	 	 	 	60	%	 	$	[***]	 	 	 	120	%	 	$	[***]	 
	 	110	%	 	 	70	%	 	$	[***]	 	 	 	70	%	 	$	[***]	 	 	 	140	%	 	$	[***]	 
	 	115	%	 	 	80	%	 	$	[***]	 	 	 	80	%	 	$	[***]	 	 	 	160	%	 	$	[***]	 
	 	120	%	 	 	90	%	 	$	[***]	 	 	 	90	%	 	$	[***]	 	 	 	180	%	 	$	[***]	 
	 	125	%	 	 	100	%	 	$	[***]	 	 	 	100	%	 	$	[***]	 	 	 	200	%	 	$	[***]	 

Example

     Assume a participant’s base salary is $200,000 and his target Performance Award is 30% of his
base salary, or $60,000. If 75% of each of the revenue and EBITDA targets is achieved, the
executive’s actual Performance Award will be 50% of his target Performance Award, or $30,000. If
100% of each of the revenue and EBITDA targets is achieved, the executive’s actual Performance
Award will be 100% of his target Performance Award, or $60,000. If 125% of each of the revenue and
EBITDA targets is achieved, the executive’s actual Performance Award will be 200% of his target
Performance Award, or $120,000.

Determination of Performance Awards

     The Committee (as defined in the Plan), in its sole discretion, shall determine the extent to
which the revenue and EBITDA targets have been achieved, and the amount of the Performance Awards
for each Participant for the 2009 fiscal year in accordance with the terms of the Plan. Subject to
the terms of the Plan, the Committee has all discretion and authority necessary or appropriate to
administer the Plan and the Performance Awards, including, but not limited to, the power to
interpret the Plan, to prescribe, amend and rescind rules and regulations relating to it, and to
make all other determinations necessary or advisable in the administration of the Plan and the
Performance Awards, and all such determinations shall be final and binding upon all Participants
and persons having an interest in the Plan.

 

			
	[***]	 	Means that certain confidential information has been deleted from this document and filed
separately with the Securities and Exchange Commission.

2exv10w1

Exhibit 10.1

FIRST AMENDMENT TO NOTE PURCHASE AGREEMENT

     This First Amendment (the “First Amendment”) to that certain Note Purchase Agreement
(the “Note Purchase Agreement”), dated as of October 27, 2008, by and among Clinical Data,
Inc., a Delaware corporation (“Buyer”), and Avalon Pharmaceuticals, Inc., a Delaware
corporation (the “Seller”), hereby amends the Note Purchase Agreement effective as of this 30th day
of March, 2009, as follows:

     Whereas, pursuant to Section 2.1 of the Note Purchase Agreement, Seller issued to
Buyer a term note in the principal amount of Three Million Dollars ($3,000,000) with a maturity
date of March 31, 2009;

     Whereas, the Seller has agreed to issue, and Buyer has agreed to purchase, a new term
note in the principal amount of One Million Dollars ($1,000,000) with a maturity date of May 31,
2009; and

     Whereas, the parties desire to amend the Note Purchase Agreement to provide for the
issuance of such new term note;

     Now, Therefore, in consideration of the covenants and agreements set forth herein and
for other good and valuable consideration, the receipt and sufficiency of which are hereby mutually
acknowledged, the parties hereto covenant and agree as follows:

	 	1.	 	All capitalized terms not otherwise defined herein shall have their respective
meanings as defined in the Note Purchase Agreement.
	 
	 	2.	 	Section 2.1 of the Note Purchase Agreement is hereby deleted in its entirety
and is replaced by the following:
	 
	 	 	 	“Investment. Seller shall issue to Buyer (i) at Closing, a term note in the
principal amount of Three Million Dollars ($3,000,000) in the form attached hereto
as Exhibit 2.1 (the “2008 Note”), and (ii) on March 30, 2009, a term note in the
principal amount of One Million Dollars ($1,000,000) in the form attached hereto as
Exhibit 2.1(A) (the “2009 Note” and together with the 2008 Note, the “Note”).
Amounts due under the 2008 Note and the 2009 Note shall be repaid according to the
terms of the 2008 Note, the 2009 Note and this Agreement. Payments received by the
Buyer in respect of the Obligations shall be allocated in the manner set forth in
Section 2.5.”
	 
	 	3.	 	References to the “Note” in the Note Purchase Agreement shall be deemed to
include, collectively, the 2008 Note and the 2009 Note, except in such instances where
such inclusion would be unreasonable.
	 
	 	4.	 	The Note Purchase Agreement is hereby amended by adding Exhibit 2.1(A) attached
hereto as new Exhibit 2.1(A) to the Note Purchase Agreement.

 

 

	 	5.	 	The definition of “Investment” set forth in Section 1.1 of the Note Purchase
Agreement is hereby deleted in its entirety and is replaced by the following:
	 
	 	 	 	“‘Investment’ shall mean the purchase of the 2008 Note and the 2009 Note by the
Buyer from Seller on the Closing Date and March 30, 2009, respectively.”
	 
	 	6.	 	The obligation of the Buyer to purchase the 2009 Note is subject to the
satisfaction of the following conditions precedent at or prior to the date of this
First Amendment (unless waived in writing by the Buyer prior such date):

	 	6.1	 	Seller must have performed all of its obligations under the
Note Purchase Agreement and this First Amendment.
	 
	 	6.2	 	The Buyer shall have received each of the following items:

	 	6.2.1	 	This First Amendment, duly executed by Seller;
	 
	 	6.2.2	 	The 2009 Note, duly executed by Seller;
	 
	 	6.2.3	 	A certificate signed by the Secretary of
Seller certifying the resolutions adopted by Seller’s board of
directors authorizing the transactions contemplated hereby; and
	 
	 	6.2.4	 	Such other documents and certificates that
Buyer may reasonably require for purposes of effecting the transactions
contemplated by this First Amendment and the 2009 Note.

	 	7.	 	The Note Purchase Agreement and all terms therein not so amended by this First
Amendment shall remain in full force and effect pursuant to its terms as amended
hereby.
	 
	 	8.	 	This First Amendment may be executed in any number of counterparts, all of
which taken together shall constitute one and the same instrument, and each of the
parties hereto may execute this First Amendment by signing any of such counterparts.

* * * * *

2.

 

     In Witness Whereof, Buyer and Seller have executed this First Amendment to Note
Purchase Agreement as of the date first above mentioned.

	 	 	 	 	 
	 	Clinical Data, Inc.

 	 
	 	By:  	

/s/ Caesar J. Belbel
 	 
	 	 	Name:  	Caesar J. Belbel 	 
	 	 	Title:  	Executive Vice President,

Chief Legal Officer and Secretary 	 
	 
	 	

Avalon Pharmaceuticals, Inc.

 	 
	 	By:  	/s/ Kenneth C. Carter
 	 
	 	 	Name:  	Kenneth C. Carter 	 
	 	 	Title:  	President and Chief Executive Officer 	 
	 

Note Purchase Agreement Amendment Signature Page

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00156-of-00352.parquet"}]]